Subject accountability, Proc MIXED or equivalent [Regulatives / Guidelines]

posted by Ohlbe – France, 2008-09-02 17:20 (6510 d 16:43 ago) – Posting: # 2304
Views: 28,479

Dear DLabes,

❝ As is known in the standard 2x2 cross-over subjects with missing data do not contribute to the ratio or difference of Test versus Reference. Only the variability is affected, usually to a minor extent.


I'm not sure I get your point there. In a standard 2x2 cross-over trial, the new version of the guideline would still allow subjects missing one of the two periods to be excluded.

'All treated subjects should be included in the statistical analysis, with the exception of subjects in a crossover trial who do not complete at least one period receiving each of the test and reference products (or who fail to complete the single period in a parallel group trial)'.


IMHO this would apply in the case of a trial with 3 treatments or more (include subjects for whom you have data for at least one reference product and one test product) or replicate design trials (include subjects who have completed at least one period for the test and one for the reference).

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
263 visitors (0 registered, 263 guests [including 23 identified bots]).
Forum time: 10:03 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5